Related Experiment Video
Updated: Nov 11, 2025
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
Published on: April 3, 2018
The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic
Kaitlin M Dailey1,2, JuliAnne E Allgood3, Paige R Johnson2
1Cellular & Molecular Biology Program, North Dakota State University, Fargo, ND 58103, USA.
Abstract:
The development of a 'smart' drug capable of distinguishing tumor from host cells has been sought for centuries, but the microenvironment of solid tumors continues to confound therapeutics. Solid tumors present several challenges for current oncotherapeutics, including aberrant vascularization, hypoxia, necrosis, abnormally high pH and local immune suppression. While traditional chemotherapeutics are limited by such an environment, oncolytic microbes are drawn to it - having an innate ability to selectively infect, colonize and eradicate solid tumors. Development of an oncolytic species would represent a shift in the cancer therapeutic paradigm, with ramifications reaching from the medical into the socio-economic. Modern genetic engineering techniques could be implemented to customize 'Frankenstein' bacteria with advantageous characteristics from several species.
Insights
Oncolytic microbes can overcome solid tumor challenges that limit traditional cancer drugs. Genetic engineering can create advanced bacterial therapies for targeted tumor eradication.
Area of Science:
- Oncology
- Microbiology
- Biotechnology
Background:
- Solid tumors possess unique microenvironments (aberrant vascularization, hypoxia, high pH, immune suppression) that impede conventional therapies.
- Traditional chemotherapeutics struggle within these hostile tumor microenvironments.
- Oncolytic microbes naturally thrive in and target these specific tumor conditions.
Purpose of the Study:
- To explore the potential of oncolytic microbes as a novel therapeutic strategy for solid tumors.
- To highlight the advantages of microbial-based therapies over traditional chemotherapeutics.
- To discuss the application of genetic engineering in developing customized bacterial cancer treatments.
Main Methods:
- Review of existing literature on tumor microenvironments and oncolytic microbes.
- Analysis of the challenges posed by solid tumors to current oncotherapeutics.
- Exploration of genetic engineering techniques for bacterial customization.
Main Results:
- Oncolytic microbes exhibit inherent selectivity for tumor cells and colonize tumor microenvironments.
- The unique conditions within solid tumors, detrimental to host cells, are favorable for oncolytic microbes.
- Genetic engineering offers a pathway to enhance the efficacy and targeting capabilities of oncolytic bacteria.
Conclusions:
- Oncolytic microbes represent a promising paradigm shift in cancer therapeutics, capable of overcoming tumor microenvironment limitations.
- Bacterial engineering can create 'designer' microbes with tailored properties for enhanced tumor eradication.
- This approach has significant medical and socio-economic implications for cancer treatment.
Related Concept Videos
01:29Microorganisms in Medicine and Therapeutics
01:33Bacterial Transformation
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
00:59Gene Therapy
01:20The Central Dogma
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
00:53Transgenic Organisms